Anti-CUGBP2 (Human) pAb

WB - 1 ug/mL for chemiluminescence detection system

The CUG-binding protein 2 (CUG-BP2), a member of the CUG-BP1 and ETR-3-like factors (CELF) family, is expressed ubiquitously, albeit at high levels in muscle cells. The physiological function of CUG-BP2 expression in the epithelial cells is still unclear. However, the in vivo targets of CUG-BP2 have been identified in cancer cells. The expression level of CUG-BP2 was increased in HT-29 colon cancer cells after irradiation with gamma rays. CUG-BP2 translocates to the cytoplasm and binds to U-rich sequences in the 3?-UTR of cyclooxygenase-2 (COX-2) mRNA, thereby increasing the stability of COX-2 mRNA while inhibiting its translation. Recent studies have reported that downregulation of CUG-BP2 expression by prostaglandin E2 protects the cells from radiation-induced mitotic catastrophe. CUG-BP2 also induces apoptosis in cancer cells by regulating the translation of McL-1, which is a member of the Bcl-2 families that perform anti-apoptotic functions, through binding to 3? UTR of McL-1 mRNA.

1 mg/mL

100 ul volume of PBS containing 50% glycerol, pH 7.2. No preservative is contained.

Human: 10659 Mouse: 14007 Rat: 29428

N-terminal region of synthetic peptide binding KLH, human CUGBP2

This antibody reacts with human, mouse, rat and hamster CUGBP2 on Western blotting.

1 year

This antibody was purified from rabbit serum by affinity column chromatography. The rabbit was immunized with KLH conjugated synthetic peptide, corresponding to N-terminus of human CUGBP2.

CUGBP2